Evidence map›Paper›PMID 41091422›Full record

ArticleDiscover oncology2025

Clinicopathological characteristics of BRCA1-associated breast carcinoma patients in Kazakhstan.

Ainur Samigatova, Nursulu Altaeva, Yerlan Suleimenov, Petr Sibiryakov, Kuantkan Zhabagin, Zhanar Zhakypbekkyzy, Bakhytzhan Seksenbaev

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Identification and Computational Analysis ofMedical sciences (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ainur SamigatovaAstana Medical University, Astana city, Kazakhstan. ainur.samigatova86@gmail.com.ORCID http://orcid.org/0000-0002-2919-8212
Nursulu AltaevaAstana Medical University, Astana city, Kazakhstan.ORCID http://orcid.org/0000-0002-8756-1462
Yerlan SuleimenovQazGene LLP, Astana city, Kazakhstan.ORCID http://orcid.org/0009-0003-2629-7164
Petr SibiryakovGeneNote LLP, Almaty city, Kazakhstan.ORCID http://orcid.org/0000-0002-2552-0323
Kuantkan ZhabaginMedical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan, Astana city, Kazakhstan.ORCID http://orcid.org/0000-0002-4304-5132
Zhanar ZhakypbekkyzyAstana Medical University, Astana city, Kazakhstan.ORCID http://orcid.org/0009-0009-4943-1980
Bakhytzhan SeksenbaevAstana Medical University, Astana city, Kazakhstan.ORCID http://orcid.org/0009-0004-4931-6935

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBreast cancer remains the leading cause of cancer-related mortality among women worldwide, including Kazakhstan. Germline mutations in the BRCA1 and BRCA2 genes play pivotal roles in the pathogenesis of breast cancer, particularly in its aggressive subtypes. Despite the well-established impact of BRCA1-associated tumors on clinical outcomes, their specific characteristics within the Kazakhstani population remain insufficiently studied. This knowledge gap underscores the necessity for further research, including the present study.

objectiveTo analyze the clinical, morphological, and molecular-biological features of BRCA1-associated breast carcinomas in Kazakhstani patients, with the aim of identifying more effective strategies for diagnosis and treatment. MATERIALS AND

methodsThis study included 86 female patients diagnosed with primary invasive breast cancer who received treatment at the Oncology Center in Astana between December 2023 and June 2024. This retrospective study was conducted at a single center. Molecular genetic testing was performed via next-generation sequencing to identify pathogenic variants in the BRCA1 gene. Clinical and pathological data were retrospectively extracted from patients' medical records.

resultsThe mean age at diagnosis for patients with BRCA1-associated breast cancer was 44 years, which is 6 years younger than that of patients without BRCA1 mutations (50 years). BRCA1 mutation carriers more frequently presented with advanced-stage disease, higher histological grade, and elevated proliferative activity. The incidence of metastasis was significantly greater among BRCA1-positive patients (41.7% vs. 5.4%, p = 0.002). Compared with BRCA1-negative tumors, BRCA1-positive carcinomas exhibit markedly lower expression of estrogen and progesterone receptors, a molecular signature characteristic of triple-negative breast cancer. DISCUSSION: The findings of this study confirm that BRCA1-associated breast carcinomas are distinguished by distinct clinicopathological features, including early onset, aggressive biological behavior, and high-grade histology. These characteristics highlight the importance of personalized treatment and diagnostic strategies and underscore the need for tailored clinical risk assessments for Kazakhstani patients.

conclusionThis study revealed significant differences in the clinical and morphological characteristics of BRCA1-associated breast carcinomas among Kazakhstani women. These results provide a foundation for improving diagnostic and therapeutic approaches in Kazakhstan and for developing population-specific clinical guidelines.

Indexed as

BRCA1Breast cancerClinicopathological characteristicsGermline mutationsHereditary breast cancerKazakhstanOncologyPARP

Identifiers

PMID41091422
PMCPMC12528645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.